2235 (2235) Fair Value & Analysis

Healthcare · Market cap HK$3.0B

2 2235 2235 · HK

PriceHK$7.32

Fair ValueHK$3.84

Upside-47.5%

Quality67/100

Watch 2235 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.68 – HK$3.84

Fair value as of: Jul 2, 2026

From 17 valuation models · updated today

Share price −2.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$5.87 – HK$9.06 · fair‑value band HK$3.68 – HK$3.84 · the HK$7.32 price screens above the HK$3.84 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2235 (2235) currently trades at HK$7.32, while our model-based Fair Value estimate is HK$3.84 — implying the stock looks roughly 47.5% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2235 generated revenue of HK$661M at a net margin of 6.1%. Revenue grew 113.0% year over year. It earns a return on equity of 2.0%. The balance sheet holds a net cash position of HK$1.4B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$661M

Revenue growth (YoY) +113%

Net margin 6.1%

Return on equity 2.0%

Free cash flow −HK$6.1M FY2025

P/E ratio 61.0

More key figures

Operating margin 4.4%

EPS (TTM) HK$-0.0100

Net cash HK$1.4B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2235 reported revenue of HK$661M in FY2025 versus HK$151M in FY2021, a compound +44.5%/yr. Reported net income was HK$40.2M in FY2025.

Revenue +44.5%/yr

FY21 HK$151M

FY22 HK$174M

FY23 HK$248M

FY24 HK$346M

FY25 HK$661M

Net income

FY21 −HK$48.2M

FY22 −HK$35.0M

FY23 −HK$125M

FY24 −HK$63.1M

FY25 HK$40.2M

Is 2235 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	82.40 MXN	-95%
Abbott Laboratories, ABTT34	R$37.76	R$6.34	-83%
Stryker Corporation S1YK34	R$79.18	R$43.78	-45%
Medtronic plc MDT	$79.27	$73.33	-7%
Boston Scientific Corporation B1SX34	R$247.01	R$234.82	-5%
Edwards Lifesciences Corporation EW	$87.45	$41.02	-53%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2235 (2235) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$3.84 versus a price of HK$7.32 — about −48% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2235?

Our model-based fair value for 2235 is HK$3.84 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.32.

What is the quality score of 2235?

2235 has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2235 (2235)?

2235 reported trailing-twelve-month revenue of about HK$661M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2235?

The net profit margin of 2235 is about 6.1%, meaning it keeps roughly 6.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.